Endovascular Engineering, Inc. Announces Positive Initial Results in ENGULF Study for Hēlo™ Thrombectomy System

ENGULF Study utilizing next generation technology in targeting pulmonary embolism MENLO PARK, Calif., Oct. 31, 2023 /PRNewswire/ — Endovascular Engineering (“E2”), a mission driven, venture-backed, medical device company focused on the development and deployment of next generation clot…

Cardio Flow Announces Completion of First Commercial Cases of Innovative FreedomFlow Orbital Atherectomy Platform—and Appointment of Chief Operating Officer

ST. PAUL, Minn.–(BUSINESS WIRE)–Cardio Flow, Inc., a privately held commercial-stage medical device company and developer of minimally invasive devices to treat peripheral artery disease (PAD), is pleased to announce the successful completion of its first commercial cases for its FreedomFlow® Orbital Atherectomy Platform following FDA clearance in late September. First Commercial Case Performed by the Cardiovascular Institute of the South (CIS) Cardio Flow announced the successful completion

Evident Vascular Announces Scientific Advisory Board and New Board Member

SAN JOSE, Calif.–(BUSINESS WIRE)–Evident Vascular, Inc. a medical technology startup developing a next-generation intravascular ultrasound (IVUS) platform leveraging artificial intelligence to enable superior imaging and streamlined workflows, announced today its Scientific Advisory Board and expansion of its Board of Directors. “It is our privilege to have this esteemed group of clinical experts on our Scientific Advisory Board. Their collective expertise and experience innovating new periph

REAL-PE Study Demonstrates Statistically Significant Lower Major Bleeding Rates with the EKOS™ Endovascular System Compared to Mechanical Thrombectomy Device for Treatment of Pulmonary Embolism

Analysis is first to compare health system-based electronic health record data for treatment of pulmonary embolism with interventional devices MARLBOROUGH, Mass., Oct. 24, 2023 /PRNewswire/ — Data from the REAL-PE study was presented today at Transcatheter Cardiovascular Therapeutics…

Endologix’s DETOUR™ System Earns Spot in Local and National Award Forums; Nominated for Prix Galien USA’s Best Medical Technology

IRVINE, Calif.–(BUSINESS WIRE)– #DETOURSystem–Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, proudly announces recent awards and nominations for its groundbreaking DETOUR System. Percutaneous Transmural Arterial Bypass (PTAB) with the DETOUR System offers a novel approach to treating complex PAD, enabling physicians to bypass lesions in the superficial femoral artery, by using conduits routed th

Press Release: Sanofi delivers first medicines from Global Health Unit’s Impact brand portfolio

Sanofi delivers first medicines from Global Health Unit’s Impact brand portfolio Paris, October 19, 2023. Sanofi has delivered the first medicines from its Global Health Unit’s not-for-profit Impact brand portfolio to the Republic of Djibouti. Enoxaparin Sodium Impact is an anticoagulant medicine indicated for the treatment of venous thromboembolism including […]